array(3) { ["company_details"]=> array(13) { ["name"]=> string(26) "Bio-RAD Laboratories, Inc." ["slug"]=> string(33) "001cd-us-bio-rad-laboratories-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920" ["description"]=> string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together. #Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics" ["address_street"]=> string(20) "1000 Alfred Nobel Dr" ["address_place"]=> string(8) "Hercules" ["address_region"]=> string(10) "California" ["founding_date"]=> string(10) "1952-02-08" ["website_domain"]=> string(11) "bio-rad.com" ["website_url"]=> string(23) "https://www.bio-rad.com" ["industry_codes"]=> array(3) { [0]=> string(42) "In Vitro and In Vivo Diagnostic Substances" [1]=> string(33) "Laboratory Analytical Instruments" [2]=> string(47) "Electromedical and Electrotherapeutic Apparatus" } ["employee_count"]=> int(7900) ["article_count"]=> int(659) } ["articles"]=> array(7) { [0]=> array(7) { ["title_en"]=> string(89) "Rumors of Qiagen and Bio-Rad merger, how much does DiaSorin risk from this potential deal" ["snippet_en"]=> string(199) "According to the Wall Street Journal, Bio-Rad Laboratories is in talks with Qiagen NV to evaluate an integration of their respective activities. Qiagen is DiaSorin's partner on Quantiferon technology" ["url"]=> string(135) "https://www.milanofinanza.it/news/voci-di-fusione-qiagen-e-bio-rad-quanto-rischia-diasorin-da-questo-potenziale-deal-202210111137542789" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f93183d4-1aa8-48b8-a014-beced4b2f852" ["source"]=> string(16) "milanofinanza.it" ["publication_date"]=> string(10) "2022-11-10" ["categories"]=> array(1) { [0]=> string(6) "Merger" } } [1]=> array(7) { ["title_en"]=> string(48) "Bio-Rad and Qiagen in Merger Talks? | CHEManager" ["snippet_en"]=> string(244) "News Bio-Rad and Qiagen in Merger Talks? 12.10.2022- Bio-Rad Laboratories is in talks to merge with fellow life-sciences company Qiagen in a deal that could be worth more than$ 10 billion, US business newspaper Wall Street Journal has reported," ["url"]=> string(73) "https://www.chemanager-online.com/en/news/bio-rad-and-qiagen-merger-talks" ["image_url"]=> NULL ["source"]=> string(21) "chemanager-online.com" ["publication_date"]=> string(10) "2022-10-12" ["categories"]=> array(3) { [0]=> string(21) "Competitive Behaviour" [1]=> string(25) "Business Model Resilience" [2]=> string(6) "Merger" } } [2]=> array(7) { ["title_en"]=> string(45) "Bio-Rad, Qiagen Are In Talks Over $10B Merger" ["snippet_en"]=> string(189) "Bio-Rad Laboratories is talks to merge with Qiagen in a deal that may be valued at more than $10 billion, The Wall Street Journal reported on Monday, citing people familiar with the matter." ["url"]=> string(77) "https://www.pymnts.com/cpi-posts/bio-rad-qiagen-are-in-talks-over-10b-merger/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ad135b15-d4e8-4ef4-8d95-af255553d96e" ["source"]=> string(10) "pymnts.com" ["publication_date"]=> string(10) "2022-10-11" ["categories"]=> array(2) { [0]=> string(21) "Competitive Behaviour" [1]=> string(6) "Merger" } } [3]=> array(7) { ["title_en"]=> string(60) "Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ" ["snippet_en"]=> string(200) "FILE PHOTO: A logo of a testing company Qiagen is seen as Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit Qiagen's facility, in" ["url"]=> string(91) "https://www.reuters.com/news/picture/diagnostics-firm-bio-rad-in-talks-to-mer-idUSKBN2R51LF" ["image_url"]=> NULL ["source"]=> string(11) "reuters.com" ["publication_date"]=> string(10) "2022-10-10" ["categories"]=> array(2) { [0]=> string(8) "Politics" [1]=> string(6) "Merger" } } [4]=> array(7) { ["title_en"]=> string(62) "Diagnostics firm Bio-Rad in talks to merge with Qiagen – WSJ" ["snippet_en"]=> string(153) "(Reuters) - California-based diagnostics company Bio-Rad Laboratories is in talks to merge with Qiagen NV, the Wall Street Journal reported on Monday,..." ["url"]=> string(87) "https://wkzo.com/2022/10/10/diagnostics-firm-bio-rad-in-talks-to-merge-with-qiagen-wsj/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/595c6ad0-c7c6-4139-8dc9-015fc2f4255f" ["source"]=> string(8) "wkzo.com" ["publication_date"]=> string(10) "2022-10-10" ["categories"]=> array(2) { [0]=> string(12) "Stock Market" [1]=> string(6) "Merger" } } [5]=> array(7) { ["title_en"]=> string(162) "Anti-nuclear Antibody (ANA) Testing Market: COVID-19 Focused Report|Featuring Abbott Laboratories and Abcam Plc among others|Technavio | Virtual-Strategy Magazine" ["snippet_en"]=> string(161) "Shape strategic responses through the phases of industry recovery Abbott Laboratories, Abcam Plc, and Bio-Rad Laboratories Inc. will emerge as major anti-nuclear" ["url"]=> string(170) "https://virtual-strategy.com/2021/06/01/anti-nuclear-antibody-ana-testing-market-covid-19-focused-reportfeaturing-abbott-laboratories-and-abcam-plc-among-otherstechnavio/" ["image_url"]=> NULL ["source"]=> string(20) "virtual-strategy.com" ["publication_date"]=> string(10) "2021-06-01" ["categories"]=> array(2) { [0]=> string(8) "Epidemic" [1]=> string(6) "Merger" } } [6]=> array(7) { ["title_en"]=> string(50) "Qiagen: Good business even without the Corona hype" ["snippet_en"]=> string(239) "02/06/2023 - Acquisitions are part of Qiagen's business model. The specialist in diagnostics has just announced the takeover of its American cooperation partner Verogen for 150 million dollars. The acquisition has specialized in forensics." ["url"]=> string(94) "https://www.wallstreet-online.de/nachricht/16522246-egbert-prior-qiagen-geschaefte-corona-hype" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c65fbbf0-ce0b-4428-b5ae-7eaf352ca9bc" ["source"]=> string(20) "wallstreet-online.de" ["publication_date"]=> NULL ["categories"]=> array(5) { [0]=> string(8) "Epidemic" [1]=> string(11) "Acquisition" [2]=> string(27) "Business Model & Innovation" [3]=> string(25) "Business Model Resilience" [4]=> string(6) "Merger" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(66) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(51) } [2]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(31) } [3]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(28) } [4]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(26) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(24) } [6]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(23) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(20) } [8]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(19) } [9]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(19) } [10]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(19) } [11]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(18) } [12]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(14) } [13]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(14) } [14]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(13) } [15]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(13) } [16]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(9) } [17]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(9) } [18]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(9) } [19]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(9) } [20]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(8) } [21]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(7) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(7) } [23]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(7) } [24]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(7) } [25]=> array(2) { ["name"]=> string(16) "Case Settlements" ["count"]=> int(6) } [26]=> array(2) { ["name"]=> string(13) "Credit Rating" ["count"]=> int(5) } [27]=> array(2) { ["name"]=> string(15) "Business Ethics" ["count"]=> int(5) } [28]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(5) } [29]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(5) } } } 001cd-us-bio-rad-laboratories-inc